“Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the EFFISAYIL® 2 and EFFISAYIL® ON trials”, J of Skin, vol. 8, no. 6, p. s492, Nov. 2024, doi: 10.25251/skin.8.supp.492.